RTX vs STRO
RTX Corporation (RTX) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
RTX currently screens at market cap $259.34B and trailing P/E 36.2. STRO currently screens at market cap $470.8M.
Not investment advice. Open the RTX and STRO stock pages for the full models.
Not investment advice.